CD274 and cancer: In keeping with the high immunogenicity of dMMR/MSI-H cancers, checkpoint inhibition using anti-PD-1/PD-L1 blockade has shown to be an effective treatment approach in patients with advanced colorectal and non-colorectal dMMR/MSI-H cancers.4–6 Nevertheless, only a third of patients treated with anti-PD-1 monotherapy obtains a durable response.